Objective: Recently, the PARTNER 2A trial reported results of transcatheter aortic valve replacement versus surgical aortic valve replacement in 2032 intermediate-risk patients at 2 years. Two hundred thirty-six patients (24%) required an access route other than transfemoral. Compared with transfemoral and surgical aortic valve replacement, nontransfemoral transcatheter aortic valve replacement was associated with a numerically higher rate of death and disabling stroke at 30 days. This underscores the need for a better alternative surgical approach for patients with marginal femoral access. We reviewed our multicenter experience with minimally invasive suprasternal transcatheter aortic valve replacement. Methods: Consecutive patients with symptomatic severe aortic stenosis at high or intermediate risk for surgical aortic valve replacement underwent suprasternal transcatheter aortic valve replacement. A commercially available transcatheter heart valve was deployed under fluoroscopic guidance through the innominate artery or ascending aorta. Using a 3-cm skin incision just above the sternal notch, the Aegis Transit System (Aegis Surgical Ltd, Galway, Ireland) provided illuminated access to the mediastinum without bone disruption. Through a purse-string suture placed in the innominate artery or ascending aorta, transcatheter aortic valve replacement proceeded similarly to the direct aortic approach. Results: Thirty patients at six medical centers successfully underwent suprasternal transcatheter aortic valve replacement. Implanted valves included 2 CoreValve and 12 Evolut-R (Medtronic, Inc, Minneapolis, MN USA), as well as 10 SAPIEN 3 and 6 SAPIEN XT (Edwards Lifesciences, Corp, Irvine, CA USA) with sizes ranging from 23 to 31 mm. Median procedure time was 90 minutes and median hospital stay was 4 days. Postoperatively, new permanent pacemaker (n = 3) was the most common Vascular Academic Research Consortium 2 complication.
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Conclusions: These data demonstrate the early clinical feasibility of suprasternal transcatheter aortic valve replacement. Key advantages of this approach include direct access to the innominate artery and ascending aorta, precise sheath control, and confident arterial closure. Additional experience is warranted to confirm these favorable results.
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(Innovations 2018;13:1-4) R ecently, Leon et al. 1 reported the results of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in 2032 intermediate-risk patients at 2 years. Patients randomized to the transfemoral (TF) cohort experienced a significantly lower rate of death or disabling stroke compared with SAVR (hazard ratio = 0.79, 95% confidence interval = 0.62-1.00, P = 0.05). Furthermore, compared with SAVR, transapical (TA) or transaortic (TAo) demonstrated no clinical advantage. Nontransfemoral TAVR was associated with a numerically higher rate of death from any cause and disabling stroke. 2 These findings underscore the need for a better alternative approach in those patients who are unsuitable for TF-TAVR.
Transcatheter aortic valve replacement through the subclavian artery (trans-subclavian [TSc]) access may offer an alternative to TA and TAo. 3 However, in a propensity-matched analysis of CoreValve extreme and high-risk patients in the US Pivotal Trial, TAo (n = 80) and TSc (n = 70) were associated with a 39.4% rate of death and disabling stroke rate at 1 year, which was higher than the rate observed for all patients (26.0). 4 Moreover, procedural limitations exist with the TSc approach. The small diameter of the arterial lumen, the proximity of the mammary artery take-off after CABG, and the horizontal orientation of the heart and aortic valve may preclude a safe TSc approach. 5 Although the working distance to the aortic valve with TSc is significantly less than TF, TSc is often associated with less precise valve positioning and deployment, when compared with TA and TAo approaches. Finally, managing vascular complications of the subclavian access site may be hampered by difficulty in obtaining proximal control behind the clavicle.
Using a suprasternal incision similar to mediastinoscopy, facilitates minimally invasive TAVR through either the innominate artery or the aorta (Fig. 1) . 7, 8 Suprasternal TAVR (SS-TAVR) avoids trauma to the chest wall (sternum, ribs, and intercostal/ pectoralis muscles) while providing direct access to the anterior and superior mediastinum. The innominate artery or ascending aorta easily accommodates any commercially available introducer sheath and has larger diameters than the carotid and subclavian arteries. The relatively short and straight path between the arteriotomy and the aortic valve annulus enables maximum control and maneuverability of the delivery sheath, which facilitates accurate valve positioning and deployment. Postoperative pain and disability are identical to standard mediastinoscopy as chest wall trauma is negligible. Moreover, because catheterization of the femoral artery and vein can be completely avoided, patients can safely ambulate immediately after recovering from anesthesia.
This novel and proprietary system was developed for general mediastinal access and has received Food and Drug Administration 510(k) notification and European CE Mark. This article describes the initial clinical outcomes for SS-TAVR using the Transit System.
METHODS
Patients with symptomatic severe aortic stenosis appropriate for TAVR but with undesirable femoral artery anatomy were evaluated for SS-TAVR at six medical centers (3 US, 1 Canada, 1 Germany, 1 Colombia). All patients underwent standard imaging and were evaluated for TAVR candidacy according to the valve manufacturer's recommendations. In addition to the standard evaluation, computed tomography angiography was performed to specifically examine the location and orientation of the innominate artery and ascending aorta relative to the sternum and the aortic valve annulus. The distance between the sternal notch and the target arterial access site and the "straightness" of the approach to the aortic valve was determined in each case. Importantly, patients with limited cervical extension and head rotation were excluded because the patients' mandible prevented unobstructed passage of the cannula device. In addition, the degree of great vessel calcification, innominate artery tortuosity, and distance from skin to arterial access site on computed tomography angiography provided valuable information to anticipate procedural success. 8 Patients who were suitable for SS-TAVR underwent informed consent after institutional review board approval, where appropriate.
All procedures were performed in a hybrid operating room under general anesthesia by a multidisciplinary team composed of cardiac surgery, cardiology, as well as anesthesiology, perfusion, and nursing. With the patient's head extended and rotated to the left, the Transit System was positioned within the anterior superior mediastinum through a 3-cm suprasternal incision. Upon obtaining exposure of the innominate artery or the ascending aorta, a double purse-string suture was placed and the valve delivery sheath positioned using fluoroscopic and echocardiographic guidance. After valve deployment and removal of the introducer sheath, the purse-string sutures were tied to secure the vascular access. In all cases, we planned immediate extubation and early ambulation.
Procedure Technique
For the SS-TAVR procedure, the anesthesiologists repositioned their equipment to allow the surgeon access to the patient's midline neck, with the head extended and rotated to the left. The transesophageal echocardiography machine was positioned to the patient's left. The cardiopulmonary bypass machine was stationed to the patient's left behind the large video display. The procedural tables for the surgeon and the cardiologist were located on the patient's right side.
To permit rapid return to ambulation after procedure, we made every effort to avoid femoral arterial and venous access. Although the internal jugular vein may be a reliable option, we generally placed the temporary pacemaker via the left subclavian vein. The right radial or brachial artery provided access for the pigtail catheter and aortic angiogram. A transverse midline (collar) incision above the sternal notch allowed surgical access to the mediastinum and the innominate artery and aorta, similar to an extended mediastinoscopy (Fig. 2) . 6 The Transit dissecting cannula helped liberate the thymic fat from the posterior sternum. Generous dissection of the retrosternal space behind the manubrium helped identify and expose the innominate artery and aorta (Fig. 3) . Exchanging the dissecting cannula for the larger transit system enabled the placement of two concentric purse-string sutures in the artery. After securing the sutures with Rumel tourniquets, an introducer needle placed in the center of the purse strings allowed passage of the flexibletip guide wire into the ascending aorta followed by placement of a stiff wire in the left ventricle. At this point, the manufacturer's recommended technique guided deployment of the transcatheter valve. After successful valve deployment, the Rumel tourniquets provided hemostasis as the introducer sheath was removed during rapid pacing. A minimally invasive knot pusher helped tie the sutures for a secure and confident vascular closure. The skin was closed routinely.
RESULT
Thirty consecutive patients underwent SS-TAVR. The valves implanted included 2 CoreValve and 12 Evolut-R (Medtronic, Inc, Minneapolis, MN USA) and 10 SAPIEN 3 and 6 SAPIEN XT (Edwards Lifesciences, Corp, Irvine, CA USA) with sizes ranging from 23 to 34 mm. Table 1 describes demographic characteristics and procedural outcomes. Median procedure time was 90 minutes and median length of stay was 4 days. In 16 patients (53%), access for angiography was through the radial artery, and in the remaining 14 patients, access was through the femoral artery. Temporary pacemaker access was through the subclavian vein in 14 patients (47%), the femoral vein in 12 patients (40%), and the jugular vein in 4 patients (13%).
Most patients had arterial delivery systems placed via the innominate artery (93%). Three had undergone previous cardiac surgery with bypass grafts on the ascending aorta. The average duration of time from skin incision to placing the purse-string suture was 27 minutes (median [range] = 20 Table 1 details all complications related to the SS-TAVR procedure. Severe conduction disturbances requiring placement of a new permanent pacemaker (n = 3) was the most common Vascular Academic Research Consortium 2 complication. In one patient, who had femoral arterial access for angiography, open femoral angioplasty was required to repair a focal arterial dissection. There were no mortalities and the median (range) hospital stay was 4(2-9) days.
DISCUSSION
In patients suitable for TF-TAVR, outcomes from the intermediate-risk PARTNER Trial ostensibly confirm the benefits of avoiding cardiopulmonary bypass and chest wall trauma. Clinical outcomes from our early experience reported herein suggest that suprasternal placement of large TAVR delivery systems and retrograde deployment of the prosthetic aortic valve may achieve benefits only seen heretofore with the TF approach. Suprasternal TAVR may lead to fewer wound complications than any other approach, because it only involves dissection of the well-vascularized soft tissue of the neck. The two concentric arterial purse strings enable a conventional and secure hemostatic closure of the access site, identical to the direct aortic approach. In contrast to the TA approach, SS-TAVR avoids any trauma to the chest wall and the left ventricular apex, which significantly reduces major bleeding complications, incisional pain and disability, and intensive care unit and hospital length of stay (4 days vs 8 days in our propensity-matched comparison of SS-TAVR to TA), while avoiding long-term sequelae of LV dysfunction. [9] [10] [11] Retrograde instrumentation across the patient's aortic arch from the femoral or subclavian arteries increases the risk for cerebral embolic events during TAVR. 12 This risk is largely avoided using the suprasternal approach through the innominate artery or ascending aorta.
Precise positioning of the transcatheter aortic valve, crucial to procedural success, improves with a shorter and less tortuous path from arterial access to the landing zone. By directly placing sheaths in the innominate artery or aorta, unlike the subclavian or carotid artery, control during valve positioning and deployment is optimized. During positioning of the transcatheter valve, the valve delivery system can be effectively maneuvered through the Transit System port, enabling precise valve orientation and providing physical support during valve deployment, both important technical adjuncts for procedural success. The working distance from the arteriotomy to the aortic valve is generally less than 12 cm, further contributing to maximum valve control during deployment. In addition, the avascular midline tissue of the suprasternal space encourages a relatively pain-free recovery.
The illuminated access port facilitates complete exposure and clear visualization of the innominate artery and ascending aorta. Another advantage is gained by avoiding major vascular complications involving the subclavian and femoral vessels. Moreover, patients are able to ambulate immediately after TAVR, which may translate into expedited recovery. The Transit System has a gentle learning curve, as demonstrated by the total clinical experience encompassed in this report. Furthermore, by securely attaching the device to the procedure table, TAVR can be accomplished by a single operator.
This early clinical multicenter experience demonstrates the feasibility of SS-TAVR using the Transit System, which is associated with exceptional exposure of the innominate artery and aorta while avoiding trauma to the chest wall. This approach may offer the advantages of precise control during valve positioning and deployment, reduced incisional pain and disability, more rapid return to ambulation and resumption of activities of daily living, less consumption of intensive care unit resources, decreased total hospital length of stay, rapid return to ambulation and resumption of normal activities of daily living, and decreased incisional pain in patients who are not suitable for TF-TAVR. Additional evaluation is needed to corroborate the clinical advantages of this new surgical approach.
